How much dividend does AB Science pay?
Over the past 12 months, AB Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AB Science is expected to pay a dividend of 0 EUR.
AB Science Dividend 2024
AB Science Dividend
0 EUR
AB Science Dividend yield
Ticker
AB.PA
ISIN
FR0010557264
WKN
A1CXBG
How much dividend does AB Science 2024 pay?
According to the latest status from July 2024, AB Science paid a total of 0 EUR per share in dividends within the last 12 months. With the current AB Science price of 1.08 EUR, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| = |
Historical AB Science Dividends
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|
Is the AB Science Dividend Safe?
AB Science has been increasing the dividend for 0 years.
Over the past 10 years, AB Science has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Dividend Details
Understanding AB Science's Dividend Distributions
AB Science’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining AB Science's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
AB Science's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in AB Science’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
AB Science Aktienanalyse
What does AB Science do?
AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AB Science stock can be added to a savings plan with the following providers: Trade Republic
Frequently Asked Questions about AB Science stock
What is the dividend yield of AB Science?
The current dividend yield of AB Science is .
When does AB Science pay dividends?
AB Science pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AB Science?
AB Science paid dividends every year for the past 0 years.
What is the dividend of AB Science?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is AB Science located?
AB Science is assigned to the 'Health' sector.
Wann musste ich die Aktien von AB Science kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AB Science from 7/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/15/2024.
When did AB Science pay the last dividend?
The last dividend was paid out on 7/15/2024.
What was the dividend of AB Science in the year 2023?
In the year 2023, AB Science distributed 0 EUR as dividends.
In which currency does AB Science pay out the dividend?
The dividends of AB Science are distributed in EUR.
Andere Kennzahlen von AB Science
Our stock analysis for AB Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
